Abstract:Importance: A global outbreak of clade IIb Monkeypox virus (MPXV) infections spread rapidly across at least 118 countries resulting in a Public Health Emergency of International Concern (PHEIC) from July 2022 to May 2023. This outbreak affected more than 99 000 persons worldwide and caused more than 33 000 infections and 60 deaths in the US. In 2024, there have been approximately 200 new infections per month in the US. On August 14, 2024, the World Health Organization declared mpox a PHEIC for a second time due to a rapid increase in infections with clade I MPXV in Central Africa. Observations: Mpox is primarily acquired through direct skin to skin contact with MPXV. With clade IIb MPXV, infections are most commonly associated with sexual activity among individuals who are gay, bisexual, and other men who have sex with men. After a median incubation period of 7 to 10 days, prodromal symptoms include fever (62%-72%), lymphadenopathy (56%-86%), myalgias (31%-55%), malaise (23%-57%), and headache (25%-55%). Skin lesions progress through 4 well-defined stages (macules, papules, vesicles, and pustules) over 2 to 4 weeks. Clade IIb MPXV is typically a self-limited illness with a low mortality rate (<0.2% in the US); however, severe illness and death may occur in immunocompromised individuals, especially those with advanced HIV (CD4 count <200 cells/μL). Mpox should be suspected in patients with potential exposure to MPXV who have skin lesions, and the diagnosis is confirmed with polymerase chain reaction testing of lesions. Management is supportive and focuses on skin care and symptom relief with analgesics. While no antiviral treatments are currently approved for mpox by the US Food and Drug Administration, several therapeutics, such as tecovirimat, brincidofovir, and vaccinia immune globulin intravenous, are available through expanded access programs or clinical trials. Vaccination with the 2-dose Modified Vaccinia Ankara-Bavarian Nordic vaccine is recommended for high-incidence populations and has an efficacy of 66% to 86%. Conclusions and relevance: Mpox is a viral infection transmitted primarily through close skin to skin contact that typically causes a self-resolving illness but can result in severe illness and death in immunocompromised individuals. First-line therapy is supportive care, although patients with severe mpox infection may be treated with advanced therapeutics. Mpox vaccination is effective and, if available, should be offered to individuals at risk of exposure to mpox.

Case report: atypical presentation of mpox with massive hematochezia and prolonged viral shedding despite tecovirimat treatment

Mpox Case Presenting With Genital Lesions and Proctitis

Clinical Features of Mpox Patients in Korea: A Multicenter Retrospective Study

Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub‐lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment

Clinical manifestations and viral kinetics of people with Mpox: A case series during the 2023 outbreak in Taiwan

Mpox reinfection: A rapid systematic review of case reports

"Mpox in MSM: Tackling Stigma, Minimizing Risk Factors, Exploring Pathogenesis, and Treatment Approaches"

Clinical features and viral load variations of Mpox: a retrospective study in Chongqing, China

Viral load dynamics and shedding kinetics of mpox infection: a systematic review and meta-analysis

Clinical presentation, viral shedding, and neutralizing antibody responses of mpox cases in South Korea: Single center experience

Severe Mpox Infections in People With Uncontrolled Human Immunodeficiency Virus

Mpox in people with HIV: A narrative review

Clinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak: A systematic review and meta‐analysis

Clinical review of human mpox

Mpox: an updated review of dermatological manifestations in the current outbreak

Mpox Virus in the Pharynx of Men Having Sex with Men: A Case Series

Clinical and Epidemiological Characteristics of Mpox Cases Identified Through Case-based Surveillance in India, July 2022-January 2023

Histopathologic Findings of Evolving Mpox Lesions

Clinical Characteristics of Human Mpox (monkeypox) in 2022: A Systematic Review and Meta-Analysis.

Epidemiological and Clinical Characteristics of Patients Admitted to a Secondary Hospital with Suspected MPOX Virus Infection: Is HIV Playing a Role?

Mpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies: A Review